Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Trial
Kalinsky, Kevin, Accordino, Melissa K, Chiuzan, Codruta, Mundi, Prabhjot S, Sakach, Elizabeth, Sathe, Claire, Ahn, Heejoon, Trivedi, Meghna S, Novik, Yelena, Tiersten, Amy, Raptis, George, Baer, Lea N, Oh, Sun Y, Zelnak, Amelia B, Wisinski, Kari B, Andreopoulou, Eleni, Gradishar, William J, Stringer-Reasor, Erica, Reid, Sonya A, O'Dea, Anne, O'Regan, Ruth, Crew, Katherine D, Hershman, Dawn L
Published in Journal of clinical oncology (20.08.2023)
Published in Journal of clinical oncology (20.08.2023)
Get full text
Journal Article
Practical diagnostic approaches to composite plasma cell neoplasm and low grade B-cell lymphoma/clonal infiltrates in the bone marrow
Hussein, Shafinaz, Gill, Kamraan, Baer, Lea N., Hoehn, Daniela, Mansukhani, Mahesh, Jobanputra, Vaidehi, Bhagat, Govind, Alobeid, Bachir
Published in Hematological oncology (01.03.2015)
Published in Hematological oncology (01.03.2015)
Get full text
Journal Article
Concomitant angiosarcoma and lymphoproliferative disorder in solid organ transplant recipients
Baer, Lea N, Savage, David G, Hibshoosh, Hanina H, Kalinsky, Kevin
Published in Clinical sarcoma research (31.10.2014)
Published in Clinical sarcoma research (31.10.2014)
Get full text
Journal Article
Translesion synthesis genes POLI and REV1 in breast tumors and response to neoadjuvant chemotherapy
Thompson, Patricia, Jones, Emma V, Preece, Christina, Li, Jinyu, Bhalla, Jigna, Cohen, Jules, Baer, Lea N., Pierce, Andrew, Stopeck, Alison
Published in Journal of clinical oncology (20.05.2020)
Published in Journal of clinical oncology (20.05.2020)
Get full text
Journal Article
A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor–positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAIN trial
Kalinsky, Kevin, Accordino, Melissa Kate, Chiuzan, Codruta, Mundi, Prabhjot Singh, Trivedi, Meghna S., Novik, Yelena, Tiersten, Amy, Raptis, George, Baer, Lea N., Young Oh, Sun, Zelnak, Amelia Bruce, Wisinski, Kari Braun, Andreopoulou, Eleni, Gradishar, William John, Stringer-Reasor, Erica, Reid, Sonya A., O'Dea, Anne, O'Regan, Ruth, Crew, Katherine D., Hershman, Dawn L.
Published in Journal of clinical oncology (10.06.2022)
Published in Journal of clinical oncology (10.06.2022)
Get full text
Journal Article
Assesment of distress among breast cancer survivors
Neerukonda, Anu Radha, Stevens, Michelle M., Reagan, Lisa, Cohen, Jules, Baer, Lea N., Messina, Catherine, Nemesure, Barbara
Published in Journal of clinical oncology (20.05.2015)
Published in Journal of clinical oncology (20.05.2015)
Get full text
Journal Article
A randomized phase II trial of fulvestrant with or without ribociclib after progression on aromatase inhibition plus cyclin-dependent kinase 4/6 inhibition in patients with unresectable or metastatic hormone receptor positive, HER2 negative breast cancer
Kalinsky, Kevin, Mundi, Prabhjot Singh, Chiuzan, Codruta, Accordino, Melissa Kate, Trivedi, Meghna S., Sparano, Joseph A., Young Oh, Sun, Tiersten, Amy, O'Regan, Ruth, Esteva, Francisco J., Jain, Sarika, Mayer, Ingrid A., Forero, Andres, Baer, Lea N., Crew, Katherine D., Hershman, Dawn L., Vaklavas, Christos
Published in Journal of clinical oncology (20.05.2017)
Published in Journal of clinical oncology (20.05.2017)
Get full text
Journal Article